Rinvoq on HealthSpring Assurance Rx (S5617-088)
upadacitinib
Covered, with prior authorization required.
Tier 5 (specialty tier). Quantity limit of 168 per 365 days.
$1,494.76
Patient pays / month, after deductible
$1,956.01
Patient pays / month, before the $615.00 deductible
Not offered
Patient pays / 90 days by mail
$0
After the yearly $2,100.00 out-of-pocket cap
RINVOQ 45 mg Tablet, Extended Release at a preferred retail pharmacy, from the plan's negotiated price of $5,979.02 for a month. Other covered strengths are listed below.
Prior authRequired on all 4 covered forms· The plan decides within 72 hours, or 24 if expedited· If denied, the prescriber can ask the plan to reconsider (an appeal)
All 4 covered strengths and forms
| Form | Tier | Patient pays / month | Limits |
|---|---|---|---|
| RINVOQ 45 mg Tablet, Extended Release | 5 | $1,494.76 | PA · 168 per 365 days |
| RINVOQ 15 mg Tablet, Extended Release | 5 | $1,635.01 | PA · 30 per 30 days |
| RINVOQ 30 mg Tablet, Extended Release | 5 | $1,606.83 | PA · 30 per 30 days |
| RINVOQ 1 mg/mL Solution | 5 | $1,622.31 | PA · 360 per 30 days |
Other JAK inhibitors on this plan
Verify with the plan before prescribing or filling. Member services: (800)222-6700. Data from the CMS 2026 Part D formulary and pricing files. Full plan details
Plan ID s5617-088